What is reactive arthritis? Reactive arthritis is pain or swelling in a joint that is caused by an infection in your body. You may also have red, swollen eyes and a swollen urinary tract. These symptoms may occur alone, together, or not at all. Most people with reactive arthritis recover fully from the first flare of symptoms and can return to regular activities 2 to 6 months later. Some people will have long-term, mild arthritis. A few patients will have long-term, severe arthritis that is difficult to control with treatment and may cause joint damage.
What is tendinitis? Tendinitis is swelling and pain in a tendon, which is tissue that connects muscles to bones. It is a common condition, usually caused by repeated injuries to a tendon.
What is atopic dermatitis? Atopic dermatitis, often called eczema, is a chronic (long-lasting) disease that causes the skin to become inflamed and irritated, making it extremely itchy. Scratching leads to: Redness. Swelling. Cracking. “Weeping” clear fluid. Crusting. Scaling. In most cases, there are times when the disease is worse, called flares, followed by times when the skin improves or clears up entirely, called remissions. Atopic dermatitis is a common condition, and anyone can get the disease. However, it usually begins in childhood. Atopic dermatitis cannot be spread from person to person. No one knows what causes atopic dermatitis. Depending on
What are arthritis and rheumatic diseases? The term arthritis is often used to refer to any disorder that affects the joints. There are more than 100 rheumatic diseases. Rheumatic diseases usually affect joints, tendons, ligaments, bones, and muscles. Some rheumatic diseases can also affect the organs.
Two types of antibody molecules act in concert to stimulate inflammation in people with rheumatoid arthritis, according to research funded in part by the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS).
Media Availability What: The U.S. Food and Drug Administration recently approved a new oral medication for the treatment of rheumatoid arthritis that represents a new class of drugs for the disease. The drug, tofacitinib (Xeljanz), provides a new treatment option for adults with moderately to severely active rheumatoid arthritis who have had an inadequate response to, or who are intolerant of, methotrexate, a standard therapy for the disease. Affecting nearly 1.5 million adults, rheumatoid arthritis is an inflammatory disease that causes pain, swelling, stiffness, and loss of function in the joints. It occurs when the immune system, which normally defends
The AMP RA/SLE Program brings together the NIH and medical community to address rheumatoid arthritis and lupus with diagnostic and drug advancements.